J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
The Journal of New Drugs, 1965; 5:199-207
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abrams, W. B.
Right arrow Articles by Bagdon, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abrams, W. B.
Right arrow Articles by Bagdon, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Investigative Methods in Clinical Toxicology

William B. Abrams M.D.1, Gerhard Zbinden M.D.2, and Robert Bagdon Ph.D.2

1 Department of Clinical Pharmacology, Hoffmann-LaRoche Inc., Nutley, N. J.
2 Hoffmann-LaRoche Inc.

The standard preclinical animal toxicologic studies currently employed are the LD50 determination in rats, pyramiding single-dose studies in dogs, and the administration of the test drug for 13 weeks in rats and 13 weeks in dogs. Chronic studies last a year or more in rats and at least six months in dogs, with a third species frequently employed as well. When the results of such studies are correlated with toxicologic experience in humans, it appears the animal experiments are successful only in eliminating highly toxic drugs from human trial and in identifying a few of the specific types of toxic reactions described. Most forms of adverse drug effects are not as yet predictable. clinical investigations must there fore seek to identify side effects as vigorously and methodically as they seek to identify efficacy. Such a search must take into account the chemical nature of the new drugs, the information provided by the pharmacologic and toxicologic animal studies, and the stage of the clinical trial.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1965 by the American College of Clinical Pharmacology